{
    "thesis_theoretical": [
        {
            "Thesis0": "The influencer suggests that the company's strong fundamentals and high growth rate are the key reasons for its impressive returns."
        },
        {
            "Thesis1": "The influencer also points out that the stock's current PE ratio is lower than the Nifty Pharma PE, suggesting that it may be undervalued."
        },
        {
            "Thesis2": "The influencer also uses the PEG ratio to argue that the stock is undervalued, as a PEG ratio of less than one is generally considered to indicate an undervalued stock."
        }
    ],
    "thesis_quantitative": [
        {
            "Thesis0": "In the last five years, the stock has given close to 2200% returns."
        },
        {
            "Thesis1": "In the last few years, the company's revenues have been growing at a rate of 26-30%, and its earnings per share have been growing at a rate of 44-32%."
        },
        {
            "Thesis2": "The stock's current PE ratio is 19, compared to the Nifty Pharma PE of 31."
        },
        {
            "Thesis3": "The stock's PEG ratio is currently 0.27."
        }
    ],
    "username": "Rahul Jain"
}